Lv1
72 积分 2022-11-08 加入
GS-005 Outcomes by liver function in patients with unresectable hepatocellular carcinoma treated with nivolumab plus ipilimumab vs lenvatinib or sorafenib in the CheckMate 9DWtrial
16天前
已完结
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
18天前
已完结
Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma
1个月前
已完结
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting
1个月前
已完结
SHR-8068 plus adebrelimab and bevacizumab for advanced hepatocellular carcinoma (aHCC): A phase 1b/2 study
1个月前
已完结
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
2个月前
已完结
The 34th Anual Meeting of the Asian Pacific Association for the study of the liver
2个月前
已关闭
Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis
3个月前
已完结
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
3个月前
已完结
Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial
3个月前
已完结
皖公网安备34019202002308
